[go: up one dir, main page]

HK40119816A - Capsule inhaler for the administration of a phosphodiesterase-4 inhibitor - Google Patents

Capsule inhaler for the administration of a phosphodiesterase-4 inhibitor

Info

Publication number
HK40119816A
HK40119816A HK62025107368.5A HK62025107368A HK40119816A HK 40119816 A HK40119816 A HK 40119816A HK 62025107368 A HK62025107368 A HK 62025107368A HK 40119816 A HK40119816 A HK 40119816A
Authority
HK
Hong Kong
Prior art keywords
phosphodiesterase
inhibitor
administration
capsule inhaler
inhaler
Prior art date
Application number
HK62025107368.5A
Other languages
Chinese (zh)
Inventor
F·布蒂尼
G·瓦拉卡
R·奥赛罗
Original Assignee
奇斯药制品公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 奇斯药制品公司 filed Critical 奇斯药制品公司
Publication of HK40119816A publication Critical patent/HK40119816A/en

Links

HK62025107368.5A 2022-09-22 2023-09-21 Capsule inhaler for the administration of a phosphodiesterase-4 inhibitor HK40119816A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP22197236.7 2022-09-22

Publications (1)

Publication Number Publication Date
HK40119816A true HK40119816A (en) 2025-07-25

Family

ID=

Similar Documents

Publication Publication Date Title
MX2022008487A (en) Smarca2-vhl degraders.
EP4054596A4 (en) Use of mog for priming a treatment for glioblastoma
EP4274557A4 (en) Oral administration of ketamine
AU2021413439A9 (en) Pharmaceutical composition for inhalation
HK40118752A (en) Capsule inhaler for the administration of a phosphodiesterase-4 inhibitor
HK40119816A (en) Capsule inhaler for the administration of a phosphodiesterase-4 inhibitor
HK40118753A (en) Capsule inhaler for the administration of a phosphodiesterase-4 inhibitor
CA3267958A1 (en) Capsule inhaler for the administration of a phosphodiesterase-4 inhibitor
IL319640A (en) Capsule inhaler for the administration of a phosphodiesterase-4 inhibitor
GB202013645D0 (en) Pharmacetical compositions for the nasal administration of a colbalamin compound
TN2012000568A1 (en) Sustained-release therapeutic agent for hypertension and renal dysfunction
EP4052699A4 (en) Orally administered solid dosage form drug
EP3773581A4 (en) Therapeutic combinations of orally administered paclitaxel and a p-gp inhibitor for the treatment of angiosarcoma
EP3976134A4 (en) Devices and methods for administering a therapeutic preparation
HK40074675A (en) A pharmaceutical oral dosage form of q203
HK40112157A (en) The pharmaceutical use of enpp1 inhibitors
AU2023904120A0 (en) Device for administering a drug
HK40100118A (en) Methods for the combined administration of deutetrabenazine and a cyp2d6 inhibitor
HK40111188A (en) Dosage forms for the delivery of a probiotic
HK40063554A (en) Applicator for oral administration of a swallowable object to a patient
CA3291597A1 (en) Medicament capsule holder for syringe
AU2024267665A1 (en) Medicament capsule holder for syringe
HK40083363A (en) A pharmaceutical combination for the treatment of a cancer
CA3278748A1 (en) Improved ear catheter for administering medication
AU2024314986A1 (en) Capsule for the preparation of a beverage